Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis Dec 16, 2021
Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program Dec 15, 2021
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis Dec 13, 2021
Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition Dec 9, 2021
Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update Nov 3, 2021
Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors Oct 14, 2021
